A systems pharmacology model for predicting effects of Factor Xa inhibitors in healthy subjects: Assessment of pharmacokinetics and binding kinetics

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 11, 2015, Pages 650-659

  Zhou, X ^a   Huntjens, D R H ^a   Gilissen, R A H J ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; RIVAROXABAN;

ADULT; ANTICOAGULATION; ARTICLE; ASSOCIATION RATE CONSTANT; BINDING KINETICS; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; BLOOD SAMPLING; BODY MASS; DISSOCIATION RATE CONSTANT; DRUG ABSORPTION; DRUG BINDING; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ELIMINATION; HUMAN; MALE; MICHAELIS MENTEN KINETICS; NORMAL HUMAN; PLASMA PROTEIN BINDING; PREDICTION; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TURNOVER TIME;

EID: 84956594806     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12035     Document Type: Article

References (48)

1. Hirsh J., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119 (suppl. 1), 8S-21S (2001
2. Ansell J., et al. Managing oral anticoagulant therapy. Chest 119 (suppl. 1), 22S-38S (2001
3. Wells P.S., Holbrook A.M., Crowther N.R., & Hirsh J. Interactions of warfarin with drugs and food. Ann. Intern. Med. 121, 676-683 (1994
4. Ageno W., et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141, e44S-88S (2012
5. Spellman G.G. Jr., & Nossel H.L. Anticoagulant activity of dog hookworm. Am. J. Physiol. 220, 922-927 (1971
6. Mann K.G., Brummel K., & Butenas S. What is all that thrombin for? J. Thromb. Haemost. 1, 1504-1514 (2003
7. Samama M.M., Meddahi S., & Samama C.M. Pharmacology and laboratory testing of the oral Xa inhibitors. Clin. Lab. Med. 34, 503-517 (2014
8. Frost C., et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin. Pharmacol. 6, 179-187 (2014
9. Copeland R.A., Pompliano D.L., & Meek T.D. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5, 730-739 (2006
10. Guo D., Hillger J.M., IJzerman A.P., & Heitman L.H. Drug-target residence time-a case for G protein-coupled receptors. Med. Res. Rev. 34, 856-892 (2014
11. Dahl G., & Akerud T. Pharmacokinetics and the drug-target residence time concept. Drug Discov. Today 18, 697-707 (2013
12. Yassen A., Olofsen E., Dahan A., & Danhof M. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J. Pharmacol. Exp. Ther. 313, 1136-1149 (2005
13. Arrowsmith J. Trial watch: phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10, 328-329 (2011
14. van Der Graaf P.H., & Benson N. Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development. Pharm. Res. 28, 1460-1464 (2011
15. Henry J.B., McPherson R.A., & Pincus M.R. Coagulation and fibrinolysis. In: Henry's Clinical Diagnosis and Management by Laboratory Methods, 22nd edn. McPherson R.A., Pincus M.R., & Henry J.B. eds. xxi, p 1543. (Elsevier/Saunders, Philadelphia, PA, 2011
16. Mueck W., Becka M., Kubitza D., Voith B., & Zuehlsdorf M. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor xa inhibitor-in healthy subjects. Int. J. Clin. Pharmacol. Ther. 45, 335-344 (2007
17. U.S. Food and Drug Administration: Apixaban clinical pharmacology and biopharmaceutics review(s). http://www. accessdata.fda.gov/drugsat.fda-docs/nda/2012/202155.Orig1s000ClinPharmR.pdf(2012). Accessed 19 August 2014
18. Orfeo T., Butenas S., Brummel-Ziedins K.E., Gissel M., & Mann K.G. Anticoagulation by factor Xa inhibitors. J. Thromb. Haemost. 8, 1745-1753 (2010
19. U.S. Food and Drug Administration: Apixaban pharmacology review(s). http://www. accessdata.fda.gov/drugsat.fda-docs/nda/2012/202155Orig1s000PharmR.pdf (2011). Accessed 16 October 2014
20. van Der Meer F.J., Koster T., Vandenbroucke J.P., Briët E., & Rosendaal F.R. The Leiden Thrombophilia Study (LETS). Thromb. Haemost. 78, 631-635 (1997
21. Brummel-Ziedins K., Vossen C.Y., Rosendaal F.R., Umezaki K., & Mann K.G. The plasma hemostatic proteome: thrombin generation in healthy individuals. J. Thromb. Haemost. 3, 1472-1481 (2005
22. Brummel-Ziedins K.E., Orfeo T., Gissel M., Mann K.G., & Rosendaal F.R. Factor Xa generation by computational modeling: an additional discriminator to thrombin generation evaluation. PLoS One 7, e29178 (2012
23. Rosencher N., Bellamy L., & Amaout L. Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery? Arch. Cardiovasc. Dis. 102, 327-333 (2009
24. Kubitza D., Becka M., Wensing G., Voith B., & Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur. J. Clin. Pharmacol. 61, 873-880 (2005
25. Frost C., et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 76, 776-786 (2013
26. Burghaus R., et al. Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation. PLoS One 6, e17626 (2011
27. U.S. Food and Drug Administration. Rivaroxaban clinical pharmacology and biopharmaceutics review(s). http://www.accessdata.fda.gov/drugsat.fda-docs/nda/2011/022406Orig1s000ClinPharmR.pdf (2009). Accessed 14 October 2014
28. Frost C.E., et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin. Pharmacokinet. 54, 651-662 (2015
29. Khanin M.A., & Semenov V.V. A mathematical model of the kinetics of blood coagulation. J. Theor. Biol. 136, 127-134 (1989
30. Tanos P.P., Isbister G.K., Lalloo D.G., Kirkpatrick C.M., & Duffull S.B. A model for venom-induced consumptive coagulopathy in snake bite. Toxicon 52, 769-780 (2008
31. Khanin M.A., Rakov D.V., & Kogan A.E. Mathematical model for the blood coagulation prothrombin time test. Thromb. Res. 89, 227-232 (1998
32. Kogan A.E., Kardakov D.V., & Khanin M.A. Analysis of the activated partial thromboplastin time test using mathematical modeling. Thromb. Res. 101, 299-310 (2001
33. Pohl B., Beringer C., Bomhard M., & Keller F. The quick machine-a mathematical model for the extrinsic activation of coagulation. Haemostasis 24, 325-337 (1994
34. Wajima T., Isbister G.K., & Duffull S.B. A comprehensive model for the humoral coagulation network in humans. Clin. Pharmacol. Ther. 86, 290-298 (2009
35. Corno A.R., et al. Automated APTT cycle for the rapid identification of plasma prekallikrein deficiency. Thromb. Res. 126, e152-e153 (2010
36. Warkentin T.E., Margetts P., Connolly S.J., Lamy A., Ricci C., & Eikelboom J.W. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatranassociated postcardiac surgery bleeding. Blood 119, 2172-2174 (2012
37. Kubitza D., Becka M., Voith B., Zuehlsdorf M., & Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 78, 412-421 (2005
38. Glauser B.F., et al. Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa. Thromb. Haemost. 102, 1183-1193 (2009
39. Ingalls B.P., & Sauro H.M. Sensitivity analysis of stoichiometric networks: an extension of metabolic control analysis to non-steady state trajectories. J. Theor. Biol. 222, 23-36 (2003
40. Takemoto C.M., et al. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance. Am. J. Clin. Pathol. 139, 450-456 (2013
41. Jesty J., & Silverberg S.A. Kinetics of the tissue factor-dependent activation of coagulation Factors IX and X in a bovine plasma system. J. Biol. Chem. 254, 12337-12345 (1979
42. Butenas S., van 't Veer C., & Mann K.G. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J. Biol. Chem. 272, 21527-21533 (1997
43. Shibeko A.M., Lobanova E.S., Panteleev M.A., & Ataullakhanov F.I. Blood flow controls coagulation onset via the positive feedback of factor VII activation by factor Xa. BMC Syst. Biol. 4, 5 (2010
44. Funk D.M. Coagulation assays and anticoagulant monitoring. Hematology Am. Soc. Hematol. Educ. Program 2012, 460-465 (2012
45. Barrett Y.C., Wang Z., Frost C., & Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb. Haemost. 104, 1263-1271 (2010
46. Roberts P.S., Hughes H.N., & Fleming P.B. The effects of hepes buffer on clotting tests, assay of factors V and VIII and on the hydrolysis of esters by thrombin and thrombokinase. Thromb. Haemost. 35, 202-210 (1976
47. Liotta E.M., Levasseur-Franklin K.E., & Naidech A.M. Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban. Curr. Opin. Crit. Care 21, 127-133 (2015
48. Siegal D.M. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J. Thromb. Thrombolysis 39, 395-402 (2015